These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 13587424)

  • 1. Effect of administration of phenindione on blood levels of prothrombin, autoprothrombin I and autoprothrombin II.
    JOHNSON SA; CALDWELL MJ; PRIEST EM
    J Appl Physiol; 1958 Nov; 13(3):411-6. PubMed ID: 13587424
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of phenylindanedione on the coagulation factors prothrombin, factor V and factor VII and the question of vitamin K resistance].
    PERLICK E
    Klin Wochenschr; 1953 Mar; 31(11-12):261-3. PubMed ID: 13070456
    [No Abstract]   [Full Text] [Related]  

  • 3. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II or autoprothrombin II-A).
    MAMMEN EF; THOMAS WR; SEEGERS WH
    Thromb Diath Haemorrh; 1960 Dec; 5():218-49. PubMed ID: 13765990
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of oral and intravenous administration of vitamins K on the prothrombin and proconvertin levels of cholecystnephrostomized dogs.
    FISHER LM; JAQUES LB; MILLAR GJ
    Can J Biochem Physiol; 1956 Sep; 34(5):1039-51. PubMed ID: 13364731
    [No Abstract]   [Full Text] [Related]  

  • 5. The influence of ACTH on prothrombin-proconvertin values in blood during treatment with dicumarol and phenylindanedione.
    HELLEM AJ; SOLEM JH
    Acta Med Scand; 1954; 150(5):389-93. PubMed ID: 13217736
    [No Abstract]   [Full Text] [Related]  

  • 6. Autoprothrombin II of human origin.
    ULUTIN ON; JOHNSON JF; SEEGERS WH
    Am J Physiol; 1961 Oct; 201():660-2. PubMed ID: 13923734
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion of prothrombin to autoprothrombin. II. (Platelet cofactor II) and its relation to the blood clotting mechanisms.
    SEEGERS WH; JOHNSON SA
    Am J Physiol; 1956 Feb; 184(2):259-64. PubMed ID: 13302408
    [No Abstract]   [Full Text] [Related]  

  • 8. Control of anticoagulant therapy. A comparison of the thrombotest, the prothrombin-proconvertin method, and the prothrombin time.
    FICHERA C
    Acta Med Scand; 1962 Sep; 172():363-7. PubMed ID: 13945019
    [No Abstract]   [Full Text] [Related]  

  • 9. INACTIVATION OF PURIFIED AUTOPROTHROMBIN I WITH ANTITHROMBIN.
    SEEGERS WH; SCHROEER H; KAGAMI M
    Can J Biochem; 1964 Oct; 42():1425-35. PubMed ID: 14240727
    [No Abstract]   [Full Text] [Related]  

  • 10. Preparation of a human plasma fraction rich in prothrombin, proconvertin, Stuart factor, and PTC and a study of its activity and toxicity in rabbits and man.
    DIDISHEIM P; LOEB J; BLATRIX C; SOULIER JP
    J Lab Clin Med; 1959 Feb; 53(2):322-30. PubMed ID: 13621053
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of synthetic vitamin K1 on prothrombin, factor VII complex and factor IX in premature infants].
    YOSHIDA K; MORII N; KANMI M; YOSHIDA K
    Paediatr Jpn; 1963 Jun; 67():373-8. PubMed ID: 14002672
    [No Abstract]   [Full Text] [Related]  

  • 12. PROTHROMBIN LEVELS DURING THE FIRST YEAR OF LIFE. OBSERVATIONS FOLLOWED BY THE SYNTHETIC SUBSTRATE (TAME) ASSAY OF NORMAL FULL-TERM INFANTS.
    GLUECK HI; SUTHERLAND J; GLESER G
    Am J Dis Child; 1964 Jun; 107():612-7. PubMed ID: 14133821
    [No Abstract]   [Full Text] [Related]  

  • 13. The levels of factors II, VII, IX and X by antibody neutralization techniques in the plasma of patients receiving phenindione therapy.
    Denson KW
    Br J Haematol; 1971 Jun; 20(6):643-8. PubMed ID: 5089955
    [No Abstract]   [Full Text] [Related]  

  • 14. EFFECT OF ORAL ANTICOAGULANTS ON FACTORS VII, IX, X, AND II.
    KAZMIER F; SPITTELL JA; THOMPSON JJ; OWEN CA
    Arch Intern Med; 1965 Jun; 115():667-73. PubMed ID: 14299436
    [No Abstract]   [Full Text] [Related]  

  • 15. [Modification of coagulation factor IX by hydroxycoumarin and phenylindandione derivatives].
    EGLI H; SCHNEIDER W
    Thromb Diath Haemorrh; 1961 Sep; 6():331-8. PubMed ID: 13889446
    [No Abstract]   [Full Text] [Related]  

  • 16. Conversion of prothrombin to autoprothrombin II.
    DUCKERT F; JOHNSON SA; PENNER JA; SEEGERS WH
    Can J Biochem Physiol; 1956 Nov; 34(6):1199-209. PubMed ID: 13374584
    [No Abstract]   [Full Text] [Related]  

  • 17. The comparative action of dicumarol and of phenylindanedione on the coagulase reacting factor and on prothrombin.
    TAGER M
    Yale J Biol Med; 1953 Apr; 25(5):374-82. PubMed ID: 13057268
    [No Abstract]   [Full Text] [Related]  

  • 18. Behaviour of factors II, VII, IX and X during long-term treatment with coumarin.
    LOELIGER EA; van der ESCH ; MATTERN MJ; den BRABANDER AS
    Thromb Diath Haemorrh; 1963 Apr; 9():74-89. PubMed ID: 13931274
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative influence of coumadine and pindione on the prothrombin levels and coagulability index].
    BUREAU DU COLOMBIER H
    Angeiologie; 1962; 14():25-7. PubMed ID: 13874764
    [No Abstract]   [Full Text] [Related]  

  • 20. SURVIVAL TIME OF PROTHROMBIN AND FACTORS VII, IX AND X AFTER COMPLETELY SYNTHESIS BLOCKING DOSES OF COUMARIN DERIVATIVES.
    HELLEMANS J; VORLAT M; VERSTRAETE M
    Br J Haematol; 1963 Oct; 9():506-12. PubMed ID: 14076133
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.